



## GROUP TEMPLATE

# PUBLIC DECLARATION FOR IN-HOUSE DEVICES ACCORDING TO ARTICLE 5(5) OF THE IVDR AND MDR

### WRITTEN BY

Name	Role	Date	Signature
Marta Montilla	Group IVDR Manager		

### APPROVED BY

Name	Role	Date	Signature
Catherine Derrien	Head of Quality Assurance and Regulatory Affairs		

## Public Declaration for In-House devices

### Part A - Information about the manufacturing Health Institution

#### Legal Entity of the Health Institution

Name	Address
Unilabs NL	Koningsplein 1, Enschede, NL

#### List of Health Institution Sites under scope of this Public Declaration

Name	Department	Address	Contact Person
Unilabs NL	East, former Medlon	Koningsplein 1, Enschede, NL	Dr. C.J.A. Doelman, MBA

#### Contact Data of Responsible Person for the Legal Entity

Name	Job Title	Telephone Number	E-mail
Dr. C. Pronk-Admiraal, MBA	Head of Medical	+31622487929	Claudia.pronk@unilabs.com

#### Declaration

Above mentioned Health Institution states for all tests listed in part B:

- i) The device is manufactured or modified, and used in sites within the same legal entity under the scope of this Public Declaration.
- ii) The device is manufactured or modified by this Health Institution under compliant EN ISO 15189 quality management system.
- iii) The device is compliant with relevant General Safety and Performance Requirements (GSPR) as depicted in Annex I of *in vitro* Medical Device Regulation (EU) 2017/746 (IVDR) and according to Article 5 (5).
- iv) A reasoned justification is provided in case applicable General Safety and Performance Requirements are not fully met.
- v) Argumentation for use of in-house tests is documented in the quality management system, through technical file documentation.

I, the undersigned, in my capacity as **Head of Medical and legally responsible**, certify that the information given is true, accurate, present and complete to the best of my knowledge. I understand that if I have deliberately given any false information regarding any situation, I am liable against the law.

#### Signed on behalf the organisation

Responsible for the lab name <i>(Technical Director or equivalent technical role)</i>	Date	Signature
Dr. C. Pronk-Admiraal, MBA	May 24th, 2024	

#### OPTION A – TECHNICAL FILE PER FAMILY – FAMILY DECLARATION (GEN, PATH and IVD):



**Part B – Description of the In-House devices**

**In-house Family Device Name**

**List of assays or in-house devices within the Family**

#	In-house reference	In-house name	Device Type	Risk class	Intended Purpose	Applicable GSPR fully met?	Information on and justification for applicable GSPR that are not fully met (using the numbering as in Annex I of the IVDR/MDR)
1	67869	Spectrofotometrische analyse van liquor	IVD	C	Liquor analyse op bloedpigmenten	Yes	
2	67719	Sporenmatalen en zware metalen mbv ICPMS	IVD	C	Analyse van zware metalen	Yes	
3	67694	Heemsynthese metabolieten mbv LCMS	IVD	C	Verdenking op porfyrieen	Yes	
4	67685	Vet en vrije vetzuren in feces mbv FT-IR	IVD	C	Pancreasinsufficiëntie	Yes	
5	67654	Suikerabsorptietest	IVD	C	Analyse van darmpermeabiliteit	Yes	
6	67626	Niersteenanalyse mbv Infraroodspectrometrie	IVD	C	Analyse van nierstenen	Yes	
7	67625	Homocysteine in plasma	IVD	C	Analyse	Yes	
8	67590	Vitamine C in plasma	IVD	C	Analyse	Yes	
9	67589	Steenanalyse in urine, meting van citraat, glycolzuur, oxolaat, cystine en oxoprolin	IVD	C	Analyse van nierstenen	Yes	
10	67469	Serotonine in bloedplaatjes	IVD	C	Screening op en vervolgen van Feochromocytomen	Yes	



11	67468	HVA, VMA en 5-HIAA in urine	IVD	C	Screening op en vervolgen van Feochromocytomen	Yes	
12	67467	Metanefrines in urine	IVD	C	Screening op en vervolgen van Feochromocytomen	Yes	
13	67462	Dexamethason	IVD	C	Diagnostiek van Cushing	Yes	
14	67402	Melatonine in Speeksel	IVD	C	Diagnostiek van slaapstoornissen	Yes	
15	67371	Steroidprofiel in bloed	IVD	C	Diagnostiek	Yes	
16	67367	DNA analyse by myeloide aandoeningen	IVD	C	Diagnostiek van hemato-oncologische afwijkingen	Yes	
17	67318	Mutatieanalyse van Hb-pathieen	IVD	C	Diagnostiek bij verdenking Hb-pathieen	Yes	
18	67316	Conventionele PCR voor alfa-thalassemie, FLT3-ITD en FLT3-TKD	IVD	C	Diagnostiek bij hematologische afwijkingen	Yes	
19	67315	HLA B27-genotypering	IVD	C	Diagnostiek van ziekte van Bechterew	Yes	
20	67314	CYP, DPYD, Lactase, Factor II, Factor V genotypering	IVD	C	Diagnostiek bij trombose, voorspellen werking geneesmiddelen	Yes	
21	67313	Translocaties bij hemologische maligniteiten mbv RQ-PCR	IVD	C	Diagnostiek van hematologische afwijkingen	Yes	
22	67269	Trombocytenaggregatietesten	IVD	C	Diagnostiek bij stollingsstoornissen	Yes	
23	67268	Flowcytometrische analyse van cellen in bloed, beenmerg of andere lichaamsvochten	IVD	C	Diagnostiek van hematologische aandoeningen	Yes	
24	67267	Cytochemische kleuringen op bloed, beenmerg en andere lichaamsvochten	IVD	C	Diagnostiek van hematologische aandoeningen	Yes	
25	67242	Vitamine B2	IVD	C	Verdenking op deficienties	Yes	



**OPTION B – TECHNICAL FILE PER IN-HOUSE (IVD):**  
One Public Declaration by listing all the in-house tests within the same legal entity / site (if different QMS)

**Part B – Description of the In-House devices**

**List of in-house devices within the health institution**

#	In-house reference	In-house name	Device Type	Risk class	Intended Purpose	Applicable GSPR fully met?	Information on and justification for applicable GSPR that are not fully met (using the numbering as in Annex I of the IVDR/MDR)
1			(IVD or MD)	(A, B, C or D)	Refer to the corresponding form	Yes or No	Refer to the corresponding form
2							
...							

\* If desired, the table can include one column indicating which type of in-house is involved (eg developed in-house, research use only test or IVD test with modifications).